Skip to main content

S1P Modulator Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$536M
Range: $285M - $776M
Total Deal Value
$2.8B
Range: $1.7B - $3.9B
Royalty Rate
13.7% - 22.8%
Tiered up to 26.8%
Dev Milestones
$452M
Range: $290M - $616M
Model Your Deal

Market Analysis

S1P Modulator therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 s1p modulator asset in immunology & autoimmune is $536M, with total deal values reaching $2.8B. Development milestones average $452M, while regulatory milestones contribute $791M.

The immunology & autoimmune s1p modulator landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for s1p modulator immunology & autoimmune deals range from 13.7% to 22.8% at the base tier, with tiered escalation reaching 17.7%-26.8% on blockbuster sales. Commercial milestones averaging $1.0B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a s1p modulator immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 s1p modulator licensing deals in immunology & autoimmune average $536M in upfront payments, with a range of $285M to $776M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for s1p modulator immunology & autoimmune transactions?
The median total deal value for Phase 2 s1p modulator assets in immunology & autoimmune is $2.8B, ranging from $1.7B to $3.9B. This includes development milestones ($452M), regulatory milestones ($791M), and commercial milestones ($1.0B).
What royalty rates are standard for s1p modulator deals in immunology & autoimmune?
Base royalty rates for s1p modulator immunology & autoimmune transactions range from 13.7% to 22.8%, with tiered escalations reaching 17.7%-26.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in s1p modulator immunology & autoimmune deals?
S1P Modulator immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($452M) make up the largest share, followed by commercial milestones ($1.0B) and regulatory milestones ($791M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

S1P Modulator in Gastroenterology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included